Clinical trial
Phase II Study to Assess RG2417 in the Treatment of Bipolar I Depression
NCT00322764 · Repligen Corporation, Industry · Completed
Key facts
| NCT number | NCT00322764 |
|---|---|
| Title | Phase II Study to Assess RG2417 in the Treatment of Bipolar I Depression |
| Official title | Dose-Escalating, Phase II Study to Assess the Safety and Tolerability of RG2417 in the Treatment of Bipolar I Depression |
| Lead sponsor | Repligen Corporation, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Bipolar Depression |
| Intervention type | Drug |
| Interventions | Uridine |
| Enrollment | 80 |
| Start date | Mar 1, 2006 |
| First posted | May 8, 2006 |
| Last update posted | Nov 9, 2007 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: